| Clinical data | |
|---|---|
| Trade names | Increlex |
| Other names | FK-780; Recombinant human insulin-like growth factor-1; rhIGF-1; Somatomedin-1 |
| AHFS/Drugs.com | Monograph |
| Pregnancy category | |
| Routes of administration | Subcutaneous injection |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Eliminationhalf-life | 5.8 hours[3] |
| Identifiers | |
| CAS Number | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| Chemical and physical data | |
| Formula | C331H512N94O101S7 |
| Molar mass | 7648.71 g·mol−1 |
 N Y (what is this?) (verify) | |
Mecasermin, sold under the brand nameIncrelex, also known asrecombinant human insulin-like growth factor-1 (rhIGF-1), is arecombinant form of humaninsulin-like growth factor 1 (IGF-I) which is used in the long-term treatment ofgrowth failure andshort stature in children with severe primary IGF-I deficiency, for instance due togrowth hormone deficiency orLaron syndrome (growth hormone insensitivity).[3][4][5]
Mecasermin has abiological half-life of about 5.8 hours in children with severe primary IGF-1 deficiency.[3]
A related medication ismecasermin rinfabate (brand name Iplex), which is a combination of mecasermin (rhIGF-1),insulin-like growth factor binding protein-3 (IGFBP-3), andinsulin-like growth factor binding protein acid labile subunit (IGFALS) as aternary complex.[6] The complex serves to prolong the action of mecasermin in the human body; the half-life of mecasermin when provided as this complex is 13.4 hours in individuals with severe primary IGF-1 deficiency.[6]
Mecasermin therapy has been also shown to be beneficial in other conditions not related to growth failure, includingdiabetes mellitus andanorexia nervosa.[7]
